Key regions: France, India, United Kingdom, South Korea, Japan
The demand for Multiple Sclerosis (MS) drugs in Oman has been increasing in recent years, driven by various factors such as rising awareness and better healthcare facilities.
Customer preferences: Patients suffering from MS in Oman prefer drugs that are effective in managing the symptoms of the disease and have minimal side effects. They also prefer drugs that are affordable and easily accessible.
Trends in the market: One of the major trends in the MS drugs market in Oman is the increasing availability of disease-modifying therapies (DMTs). These therapies are designed to slow down the progression of the disease and reduce the frequency and severity of relapses. Another trend is the growing use of oral drugs for the treatment of MS, which are more convenient than injectable drugs. Furthermore, there is an increasing trend towards personalized medicine, where drugs are tailored to the specific needs of individual patients.
Local special circumstances: Oman has a relatively small population, which means that the market for MS drugs is relatively small compared to other countries. However, the government has been investing heavily in healthcare infrastructure and facilities, which has led to an increase in the number of patients seeking treatment. Additionally, Oman has a high prevalence of vitamin D deficiency, which is a risk factor for MS, leading to a higher incidence of the disease in the population.
Underlying macroeconomic factors: The Omani economy has been impacted by the COVID-19 pandemic, with a decline in oil prices and a reduction in government spending. However, the government has continued to prioritize healthcare spending, which has helped to sustain demand for MS drugs. The government has also implemented various initiatives to improve the availability and affordability of drugs, which has benefited patients. Overall, the MS drugs market in Oman is expected to continue to grow in the coming years, driven by increasing awareness and better healthcare facilities.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
